Metformax Sr Combi (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride lowers glucose production by the liver and increases the body’s sensitivity to insulin, while Sitagliptin inhibits the enzyme DPP‑4, prolonging the activity of incretin hormones that stimulate insulin release and suppress glucagon. Together they provide a dual approach that reduces fasting and post‑prandial blood sugar.

The dosage of Metformax Sr Combi is individualized by the prescribing healthcare professional based on factors such as the patient’s renal function, glycaemic targets, and concomitant medications. Patients should follow the exact dosing instructions provided by their prescriber and not adjust the dose without medical guidance.

Safety in pregnancy and lactation has not been fully established. The product should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers typically evaluate alternative treatments and closely monitor pregnant or nursing patients.

To place an order, submit an enquiry on the Metformax Sr Combi product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with metformin or sitagliptin alone, the combination offers dual‑mechanism glucose control in a single tablet, which can improve adherence and provide greater HbA1c reduction. Relative to other fixed‑dose combinations, it shares a similar safety profile but may differ in dosing flexibility and specific contraindications.

Store the tablets at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the packaging.

Metformax Sr Combi is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water and not crushed, chewed, or split unless specifically instructed by a healthcare professional.

The most serious adverse events include lactic acidosis, which can be life‑threatening, severe hypoglycaemia (especially when combined with insulin or sulfonylureas), and acute pancreatitis. Patients should be educated to recognize early symptoms and seek immediate medical attention if they occur.

Metformax Sr Combi is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, acute or chronic metabolic acidosis, and those with a history of lactic acidosis. Caution is also advised for individuals with significant liver disease or heart failure.